Senti Biosciences (NASDAQ:SNTI) Price Target Cut to $11.00 by Analysts at Chardan Capital

Senti Biosciences (NASDAQ:SNTI) had its price objective cut by analysts at Chardan Capital from $13.00 to $11.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other brokerages have also commented on SNTI. Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a research report on Thursday, January 22nd. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Senti Biosciences Stock Performance

NASDAQ SNTI opened at $0.79 on Monday. Senti Biosciences has a 52-week low of $0.79 and a 52-week high of $5.10. The company has a market capitalization of $20.77 million, a P/E ratio of -0.25 and a beta of 2.12. The company has a fifty day moving average of $0.95 and a 200-day moving average of $1.38.

Senti Biosciences (NASDAQ:SNTI) last released its earnings results on Friday, March 27th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.10). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $1.00 million. As a group, analysts forecast that Senti Biosciences will post -14.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Jane Street Group LLC bought a new position in shares of Senti Biosciences during the fourth quarter valued at approximately $40,000. Virtu Financial LLC bought a new stake in Senti Biosciences in the fourth quarter valued at $46,000. Citadel Advisors LLC purchased a new position in Senti Biosciences during the 3rd quarter valued at $117,000. Geode Capital Management LLC increased its position in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares during the period. Finally, Armistice Capital LLC bought a new position in Senti Biosciences in the 2nd quarter worth $1,883,000. Hedge funds and other institutional investors own 25.70% of the company’s stock.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.